An open label to evaluate the effect of atomoxetine on the improvement of quality of life in children and adolescents with ADHD, with or without other psychiatric problems.
DEC-NET Serial number IT607
Published online10/11/2006 14.50.00
Last updated20/11/2006 10.33.43
Other protocol ID numberB4Z-IT-LYDS
Current trial status
Major Disease
(ICD9 class)		ATTENTION DEFICIT DISORDER OF CHILDHOOD WITH HYPER
Experimental drug
Atomoxetine
GenderBoth
Age (range)6-15 years

Eligibility criteria

Trial design/methodology
Phase3
Kind of studyEfficacy
Safety
Design0


Sponsor name
Lilly (Industry)

ISRCTN  EudraCT